Search

Your search keyword '"Knowlton, Kirk U"' showing total 498 results

Search Constraints

Start Over You searched for: Author "Knowlton, Kirk U" Remove constraint Author: "Knowlton, Kirk U"
498 results on '"Knowlton, Kirk U"'

Search Results

451. Prediction of Long-Term Incidence of Chronic Cardiovascular and Cardiopulmonary Diseases in Primary Care Patients for Population Health Monitoring: The Intermountain Chronic Disease Model (ICHRON).

452. Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry).

453. Improving risk stratification in heart failure with preserved ejection fraction by combining two validated risk scores.

455. Kindlin-2 Is Essential for Preserving Integrity of the Developing Heart and Preventing Ventricular Rupture.

456. CHA 2 DS 2 -VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation.

457. Improving CHA 2 DS 2 -VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation.

458. Cell-Surface Marker Signature for Enrichment of Ventricular Cardiomyocytes Derived from Human Embryonic Stem Cells.

459. GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.

460. Extreme erythrocyte macrocytic and microcytic percentages are highly predictive of morbidity and mortality.

462. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.

463. Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era.

464. Real world MRI experience with nonconditional and conditional cardiac rhythm devices after MagnaSafe.

465. The association of depression at any time to the risk of death following coronary artery disease diagnosis.

467. Increased Echogenicity and Radiodense Foci on Echocardiogram and MicroCT in Murine Myocarditis.

468. Postnatal Loss of Kindlin-2 Leads to Progressive Heart Failure.

469. Lmo7 is dispensable for skeletal muscle and cardiac function.

470. Prevalence of coronary artery-pulmonary artery collaterals in patients with chronic thromboembolic pulmonary hypertension.

471. Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy.

472. Cardiac-specific deletion of SOCS-3 prevents development of left ventricular remodeling after acute myocardial infarction.

473. Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias.

474. Hypermorphic mutation of the voltage-gated sodium channel encoding gene Scn10a causes a dramatic stimulus-dependent neurobehavioral phenotype.

475. Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy.

476. The costamere bridges sarcomeres to the sarcolemma in striated muscle.

477. Loss of enigma homolog protein results in dilated cardiomyopathy.

478. Viral myocarditis: from the perspective of the virus.

480. Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart.

481. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice.

482. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy.

483. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling.

484. alpha-E-catenin inactivation disrupts the cardiomyocyte adherens junction, resulting in cardiomyopathy and susceptibility to wall rupture.

485. Prion-induced amyloid heart disease with high blood infectivity in transgenic mice.

486. Nebulin-deficient mice exhibit shorter thin filament lengths and reduced contractile function in skeletal muscle.

487. Long-term cardiac gene expression using a coxsackieviral vector.

488. Highlights of the year in JACC 2004.

489. Interleukin-10: biomarker or pathologic cytokine in fulminant myocarditis?

490. Chronic thromboembolic pulmonary hypertension.

491. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside.

492. Alternatively spliced soluble coxsackie-adenovirus receptors inhibit coxsackievirus infection.

493. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension.

494. Highlights of the year in JACC 2003.

495. Electrocardiographic manifestations: wide complex tachycardia due to accessory pathway.

496. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury.

497. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease.

498. Apoptosis and oncosis in the early progression of left ventricular dysfunction in the cardiomyopathic hamster.

Catalog

Books, media, physical & digital resources